SAN DIEGO - Revelation Biosciences Inc. (NASDAQ: REVB), a clinical-stage life sciences company, has initiated a Phase 1 clinical study in Australia to assess the safety, tolerability, and biomarker activity of Gemini, its proprietary intravenous formulation. The study targets healthy individuals aged 18 to 55 and aims to gather top-line data by this summer to inform the further development of Gemini for multiple medical conditions.
Gemini, based on phosphorylated hexaacyl disaccharide (PHAD®), is designed to activate the toll-like receptor 4 (TLR4) and potentially prime the innate immune system to better respond to stresses like ischemia or bacterial infection. The initial focus of Gemini's development is to prevent or mitigate acute kidney injury (AKI) resulting from cardiac surgery and to decrease the incidence and severity of post-surgical infections.
AKI, a growing health concern, particularly among those with conditions such as diabetes, currently lacks approved preventive treatments. Revelation's CEO, James Rolke, emphasized the significance of the study's commencement as a step toward addressing this unmet medical need and the broader issue of antibiotic resistance.
The company's preclinical studies have shown that pretreating with Gemini can lessen the impact of AKI and infections. Beyond these applications, Revelation is also exploring Gemini's potential in preventing chronic kidney disease (GEMINI-CKD program).
Revelation Biosciences is committed to leveraging trained immunity in disease prevention and treatment through Gemini, which is undergoing evaluation in various programs, including those targeting post-surgical infection and acute kidney injury.
This press release contains forward-looking statements regarding the expectations for the study's outcomes and Gemini's development. These statements are predictions and subject to risks and uncertainties that could cause actual results to differ materially from those projected. The information is based on a press release statement and does not constitute an endorsement of the company's claims.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.